• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: GYRUS ACMI, INC. VALVE IN CARTRIDGE, 7MM; SPIRATION VALVE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

GYRUS ACMI, INC. VALVE IN CARTRIDGE, 7MM; SPIRATION VALVE Back to Search Results
Model Number HUS-V7
Device Problem Migration (4003)
Patient Problem Pneumothorax (2012)
Event Type  Injury  
Event Description
Three endobronchial valves (ebv) were placed in various left sided segments to treat a bronchopleural fistula (bpf) and alveolar-pleural fistula with persistent air leak (pal) following left upper lobectomy.More than 2 years post spiration valve placement, patient presented with dyspnea on exertion, occasional small-volume hemoptysis as well as significant weight loss in the previous 6 months.A ct scan showed a pneumothorax; one ebv remained well positioned in a segmental bronchus, whereas the other 2 appeared to have migrated into the pleural space.The two valves that were found to have passed into pleural space were removed.This was an off-label use.Under this indication for use (treatment of air leak) the valves are to be removed after six weeks.
 
Manufacturer Narrative
Article discovered during literature search review: "j bronchol intervent pulmonol volume 24, number 2, april 2017; doi: 10.1097/lbr.0000000000000352; trevor m.Taylor, md, robert j.Lentz, md, fabien maldonado, md, fccp" no dates of implant or extraction were provided in the article, which was published in april 2017.Valve sizes also not provided.This was an off-label use.Under this indication for use (treatment of air leak) the valves are to be removed after six weeks.Pneumothorax is the most common device related serious adverse event that is associated with the spiration valve system.In the emprove study, the incidence of serious pneumothorax was 14.2%, with over 75% of the serious pneumothorax events occurring within the first 3 days post-procedure.Early-onset pneumothorax in the treatment group likely resulted from lung conformation changes due to acute reduction in lung volume by valve therapy, triggering rapid expansion of the ipsilateral non-targeted lobe leading to pneumothorax.(criner gj, delage a, voelker k, et al.Improving lung function in severe heterogenous emphysema with the spiration® valve system (emprove): a multicenter, open-label, randomized control trial.Am j respir crit care med.2019;200(11):1354-1362.Doi:10.1164/rccm.201902-0383oc).However, it should be noted that pneumothorax events are also recognized as an indicator of successful target lobe occlusion and when managed according to published expert guidelines (valipour a, slebos dj, de oliveira hg, et al.Expert statement: pneumothorax associated with endoscopic valve therapy for emphysema -- potential mechanisms, treatment algorithm and case examples.Respiration 2004 2014;87(6): 513-521.Doi:10.1159/000360642), subjects with pneumothorax events experienced clinical benefits similar to that in subjects without pneumothorax events (criner gj, delage a, voelker k, et al.Improving lung function in severe heterogenous emphysema with the spiration valve system (emprove).A multicenter, open-label, randomized control trial.Am j respir crit care med.2019;200(11):1354-1362.Doi:10.1164/rccm.201902-0383oc).The reported event aligns with the experience in the emprove clinical trial and is an expected adverse event associated with the spiration valve system.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
VALVE IN CARTRIDGE, 7MM
Type of Device
SPIRATION VALVE
Manufacturer (Section D)
GYRUS ACMI, INC.
6675 185th ave ne
redmond WA 98052
Manufacturer (Section G)
GYRUS ACMI, INC.
6675 185th ave ne
redmond WA 98052
Manufacturer Contact
todd brill
800 west park drive
westborough, MA 01581
5082077661
MDR Report Key16069805
MDR Text Key306353816
Report Number3004450998-2022-00029
Device Sequence Number1
Product Code OAZ
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
HDE H060002
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature,Company Representative
Reporter Occupation Other
Type of Report Initial
Report Date 12/29/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/29/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberHUS-V7
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Date Manufacturer Received12/01/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
-
-